Diagnostic Sonography

Most of the research and development of ultrasound contrast agents (UCAs) has centered on creating agents that can:

Vascular ultrasound agents enhance Doppler flow signals by:

For a vascular ultrasound contrast agent to be clinically useful, it should:

Depending on the clinical application, vascular UCAs may be administered via:

The microbubbles of tissue-specific UCAs are:

When insonating microbubble-based UCAs, the acoustic pressure present within the acoustic field:

Ultrasound contrast agents have shown the potential to improve the accuracy of hepatic sonography including:

Which of the following vessels are the first to demonstrate contrast enhancement in the liver?

The first ultrasound contrast agent to receive FDA approval was used in:

Evaluation of a patient with known cirrhosis often demonstrates a(n):

In harmonic-imaging mode, the echoes from the oscillating microbubbles have a:

The mechanical index (MI) uses:

The detection of flow in the hepatic capillaries is identified in the ___________ phase.

When using ultrasound contrast agents, a lesion that gets progressively echogenic over time is most likely:

Hepatic cavernous hemangiomas demonstrate only peripheral enhancement during the:

Several reports have described the contrast-enhanced sonographic appearance of hepatocellular carcinoma as having intense enhancement in the _____________ phase.

In the early arterial phase, using tissue-specific contrast agents, focal nodular hyperplasia can have a similar appearance to a:

The rupture of microbubbles results in random:

Tissue-specific ultrasound contrast agents can be considered to be:

Induced acoustic-emission effects are independent of: